October 11, 2004

12 Min Read
Cognitive Function References

Jan. 31, 2005 - Natural Products Industry INSIDER
"Cognitive Function" References

1. Evans JG, Wilcock G, Birks J. "Evidence-based pharmacotherapy ofAlzheimer's disease." Int J Neuropsychopharmacol. 7, 3:351-69, 2004.http://uk.cambridge.org/journals/pnp

2. Youdim KA, Joseph JA. "A possible emerging role of phytochemicals inimproving age-related neurological dysfunctions: a multiplicity ofeffects." Free Rad Biol Med. 30, 6:583-94, 2001. www.elsevier.com/locate/freeradbiomed

3. Whalley LJ, Starr JM, Deary IJ. "Diet and dementia." J BrMenopause Soc. 10, 3:113-7, 2004.

4. Bourre JM. "[The role of nutritional factors on the structure andfunction of the brain: an update on dietary requirements.]" Rev Neurol(Paris). 160, 8-9:767-92, 2004.

5. Garcia A, Zanibbi K. "Homocysteine and cognitive function in elderlypeople." CMAJ. 171, 8:897-904, 2004.

6. Gallucci M et al. "Homocysteine in Alzheimer disease and vasculardementia." Arch Gerontol Geriatr Suppl. 9:195-200, 2004.

7. Ravaglia G et al. "Homocysteine and cognitive performance in healthyelderly subjects." Arch Gerontol Geriatr Suppl. 9:349-57, 2004.

8. Luchsinger JA et al. "Plasma homocysteine levels and risk ofAlzheimer disease." Neurology. 62, 11:1972-6, 2004. www.neurology.org

9. Morris MS. "Folate, homocysteine and neurological function." NutrClin Care. 5, 3:124-32, 2002.

10. Malouf M, Grimley EJ, Areosa SA. "Folic acid with or without vitaminB12 for cognition and dementia." Cochrane Database Syst Rev.4:CD004514, 2003. www.medlib.com/spi/cdsr.htm

11. Ellinson M, Thomas J, Patterson A. "A critical evaluation of therelationship between serum vitamin B, folate and totally homocysteine withcognitive impairment in the elderly." J Hum Nutr Diet. 17, 4:371-83,2004. www.blackwell-science.com

12. Quadri P et al. "Homocysteine, folate and vitamin B-12 in mildcognitive impairment, Alzheimer disease and vascular dementia." Am JClin Nutr. 80, 1:114-22, 2004. www.ajcn.org

13. Engelborghs S et al. "Correlations between cognitive, behavioral andpsychological findings and levels of vitamin B12 and folate in patients withdementia." Int J Geriatr Psychiatry. 19, 4:365-70, 2004.

14. Wolters M, Strohle A, Hahn A. "[Age-associated changes in themetabolism of vitamin B(12) and folic acid: prevalence, aetiopathogenesis andpathophysiological consequences.]" Z Gerontol Geriatr. 37, 2:109-35,2004.

15. Malouf R, Areosa SA. "Vitamin B12 for cognition." CochraneDatabase Syst Rev. 3:CD004326, 2003. www.medlib.com/spi/cdsr.htm

16. Malouf R, Grimley EJ. "The effect of vitamin B6 on cognition." CochraneDatabase Syst Rev. 4:CD004393, 2003. www.medlib.com/spi/cdsr.htm

17. Bryan J, Calvaresi E. "Associations between dietary intake of folateand vitamins B-12 and B-6 and self-reported cognitive function and psychologicalwell-being in Australian men and women in midlife." J Nutr Health Aging.8, 4:226-32, 2004. www.springerpub.com

18. Aisen PS et al. "A pilot study of vitamins to lower plasmahomocysteine levels in Alzheimer disease." Am J Geriatr Psychiatry.11, 2:246-9, 2003.

19. Grundman M, Grundman M, Delaney P. "Antioxidant strategies forAlzheimer's disease." Proc Nutr Soc. 61, 2:191-202, 2002. www.cabi-publishing.org/journals/pns

20. Calabrese V, Butterfield DA, Stella AM. "Nutritional antioxidantsand the heme oxygenase pathway of stress tolerance: novel targets forneuroprotection in Alzheimer's disease." Ital J Biochem. 52,4:177-81, 2003.

21. Engelhart MJ et al. "Dietary intake of antioxidants and the risk ofAlzheimer disease." JAMA. 287, 24:3223-9, 2002. www.jama.ama-assn.org

22. Polidori MC et al. "Plasma antioxidant status, immunoglobulin goxidation and lipid peroxidation in demented patients: relevance to Alzheimerdisease and vascular dementia." Dement Geriatr Cogn Disord. 18,3-4:265-70, 2004.

23. Morris MC et al. "Dietary intake of antioxidant nutrients and therisk of incident Alzheimer disease in a biracial community study." JAMA.287, 24:3230-7, 2002. www.jama.ama-assn.org

24. Gray SL et al. "Is antioxidant use protective of cognitive functionin the community-dwelling elderly?" Am J Geriatr Pharmacother. 1,1:3-10, 2003.

25. Zandi PP et al. "Reduced risk of Alzheimer disease in users ofantioxidant vitamin supplements: the Cache County Study." Arch Neurol.61, 1:82-8, 2004. http://archneur.ama-assn.org

26. Masaki KH et al. "Association of vitamin E and C supplement use withcognitive function and dementia in elderly men." Neurology. 54,6:1265-72, 2000. www.neurology.org

27. Laurin D et al. "Midlife dietary intake of antioxidants and risk oflate-life incident dementia: the Honolulu-Asia Aging Study." Am JEpidemiol. 159, 10:959-67, 2004. www.aje.oupjournals.org

28. Luchsinger JA et al. "Antioxidant vitamin intake and risk ofAlzheimer disease." Arch Neurol. 60, 2:203-8, 2003. http://archneur.ama-assn.org

29. Vina J et al. "Molecular bases of the treatment of Alzheimer'sdisease with antioxidants: prevention of oxidative stress." Mol AspectsMed. 25, 1-2:117-23, 2004. www.sciencedirect.com/science/journal/00982997

30. Berman K, Brodaty H. "Tocopherol (vitamin E) in Alzheimer's diseaseand other neurodegenerative disorders." CNS Drugs. 18, 12:807-25,2004.

31. Sen CK et al. "Tocotrienol potently inhibits glutamate-inducedpp60(c-src) kinase activation and death of HT4 neuronal cells: molecular basisof vitamin E action." J Biol Chem. 275, 17:13049-55, 2000. www.jbc.org

32. Roy S et al. "Vitamin E sensitive genes in the developing rat fetalbrain: a high-density oligonucleotide microarray analysis." FEBS Letters.530, 1:17-23, 2002. www.febsletters.org.

33. Farr SA et al. "The antioxidants alpha-lipoic acid andN-acetylcysteine reverse memory impairment and brain oxidative stress in agedSAMP8 mice." J Neurochem. 84, 5:1173-83, 2003. http://highwire.stanford.edu/jneurochem.shtml?uri=/

34. Sharma M, Gupta YK. "Effect of alpha-lipoic acid onintracerebroventricular streptozotocin model of cognitive impairment inrats." Eur Neuropsychopharmacol. 13, 4:241-7, 2003. www.sciencedirect.com/science/journal/0924977X

35. Lovell MA et al. "Protection against amyloid beta peptide andiron/hydrogen peroxide toxicity by alpha-lipoic acid." J Alzheimers Dis.5, 3:229-39, 2003. www.j-alz.com

36. Youdim KA et al. "Dietary flavonoids as potentialneuroprotectants." Biol Chem. 383, 3-4:503-19, 2002. www.kfinder.de/toc/degruyter/Biological_Chemistry.htm

37. Ishige K, Schubert D, Sagara Y. "Flavonoids protect neuronal cellsfrom oxidative stress by three distinct mechanisms." Free Rad Biol Med.30, 4:433-46, 2001. www.elsevier.com/locate/freeradbiomed

38. Commenges D et al. "Intake of flavonoids and risk of dementia."Eur J Epidemiol. 16, 4:357-63, 2000.

39. Heo HJ et al. "Effect of antioxidant flavanone, naringenin, fromCitrus junoson neuroprotection." J Agric Food Chem. 52, 6:1520-5,2004. http://pubs.acs.org/journals/jafcau

40. Peng QL, Buz'Zard AR, Lau BH. "Pycnogenol protects neurons fromamyloid-beta peptide-induced apoptosis." Brain Res Mol Brain Res.104, 1:55-65, 2002.

41. Singh A, Naidu PS, Kulkarni SK. "Reversal of aging and chronicethanol-induced cognitive dysfunction by quercetin, a bioflavonoid." FreeRad Res. 37, 11:1245-52, 2003. www.tandf.co.uk/journals

42. Ono K et al. "Potent anti-amyloidogenic and fibril-destabilizingeffects of polyphenols in vitro: implications for the prevention andtherapeutics of Alzheimer's disease." J Neurochem. 87, 1:172-81,2003. http://highwire.stanford.edu/jneurochem.shtml?uri=/

43. Bastianetto S, Zheng WH, Quirion R. "Neuroprotective abilities ofresveratrol and other red wine constituents against nitric oxide-relatedtoxicity in cultured hippocampal neurons." Br J Pharmacol. 131,4:711-20, 2000.

44. Jang JH, Surh YJ. "Protective effect of resveratrol onbeta-amyloid-induced oxidative PC12 cell death." Free Rad Biol Med.34, 8:1100-10, 2003. www.elsevier.com/locate/freeradbiomed

45. Sharma M, Gupta YK. "Chronic treatment with trans resveratrolprevents intracerebroventricular streptozotocin induced cognitive impairment andoxidative stress in rats." Life Sci. 71, 21:2489-98, 2002. www.sciencedirect.com/science/journal/00243205

46. Mandel S, Youdim MB. "Catechin polyphenols: neurodegeneration andneuroprotection in neurodegenerative diseases." Free Rad Biol Med.37, 3:304-17, 2004. www.elsevier.com/locate/freeradbiomed

47. Choi YT et al. "The green tea polyphenol (-)-epigallocatechingallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampalneurons." Life Sci. 70, 5:603-14, 2001. www.sciencedirect.com/science/journal/00243205

48. Unno K et al. "Suppressive effect of green tea catechins onmorphologic and functional regression of the brain in aged mice with acceleratedsenescence (SAMP10)." Exp Gerontol. 39, 7:1027-34, 2004.

49. Lephart ED et al. "Neurobehavioral effects of dietary soyphytoestrogens." Neurotoxicol Teratol. 24, 1:5-16, 2002.

50. Lee YB et al. "Soy isoflavones improve spatial delayedmatching-to-place performance and reduce cholinergic neuron loss in elderly malerats." J Nutr. 134, 7:1827-31, 2004. www.nutrition.org

51. Bang OY et al. "Neuroprotective effect of genistein against betaamyloid-induced neurotoxicity." Neurobiol Dis. 16, 1:21-8, 2004.

52. Kritz-Silverstein D et al. "Isoflavones and cognitive function inolder women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study." Menopause.10, 3:196-202, 2003. www.menopausejournal.com

53. Duffy R, Wiseman H, File SE. "Improved cognitive function inpostmenopausal women after 12 weeks of consumption of a soya extract containingisoflavones." Pharmacol Biochem Behav. 75, 3:721-9, 2003. www.elsevier.com/locate/pharmbiochembeh

54. Kreijkamp-Kaspers S et al. "Effect of soy protein containingisoflavones on cognitive function, bone mineral density and plasma lipids inpostmenopausal women: a randomized, controlled trial." JAMA. 292,1:65-74, 2004. www.jama.ama-assn.org

55. Bourre JM. "Roles of unsaturated fatty acids (especially omega-3fatty acids) in the brain at various ages and during aging." J NutrHealth Aging. 8, 3:163-74, 2004. www.springerpub.com

56. Haag M. "Essential fatty acids and the brain." Can J Psych.48, 3:195-203, 2003. www.cpa-apc.org/Publications/cjpHome.asp

57. Cooper JL. "Dietary lipids in the aetiology of Alzheimer's disease:implications for therapy." Drugs Aging. 20, 6:399-418, 2003.

58. Kalmijn S et al. "Dietary intake of fatty acids and fish in relationto cognitive performance at middle age." Neurology. 62, 2:275-80,2004. www.neurology.org

59. Engelhart MJ et al. "Diet and risk of dementia: Does fat matter?:The Rotterdam Study." Neurology. 59, 12:1915-21, 2002. www.neurology.org

60. Morris MC et al. "Consumption of fish and n-3 fatty acids and riskof incident Alzheimer disease." Arch Neurol. 60, 7:940-6, 2003. http://archneur.ama-assn.org

61. Tully AM et al. "Low serum cholesterol ester-docosahexaenoic acidlevels in Alzheimer's disease: a case-control study." Br J Nutr. 89,4:483-9, 2003. www.cabi-publishing.org/journals/bjn

62. Jia JP et al. "Differential acetylcholine and choline concentrationsin the cerebrospinal fluid of patients with Alzheimer's disease and vasculardementia." Chin Med J (Engl). 117, 8:1161-4, 2004.

63. Dickinson-Anson H et al. "Acetylcholine-secreting cells improveage-induced memory deficits." Mol Ther. 8, 1:51-61, 2003.

64. Amenta F, Di Tullio MA, Tomassoni D. "The cholinergic approach forthe treatment of vascular dementia: evidence from pre-clinical and clinicalstudies." Clin Exp Hypertens. 24, 7-8:697-713, 2002. www.dekker.com/servlet/product/productid/CEH

65. Higgins JP, Flicker L. "Lecithin for dementia and cognitiveimpairment." Cochrane Database Syst Rev. 3:CD001015, 2003. www.medlib.com/spi/cdsr.htm

66. Amenta F et al. "Treatment of cognitive dysfunction associated withAlzheimer's disease with cholinergic precursors. Ineffective treatments orinappropriate approaches?" Mech Ageing Dev. 122, 16:2025-40, 2001. www.elsevier.com/locate/mechagedev

67. Jorissen BL et al. "Safety of soy-derived phosphatidylserine inelderly people." Nutr Neurosci. 5, 5:337-43, 2002. www.tandf.co.uk/journals/titles/1028415x.html

68. Suzuki S et al. "Oral administration of soybean lecithintransphosphatidylated phosphatidylserine improves memory impairment in agedrats." J Nutr. 131, 11:2951-6, 2001. www.nutrition.org

69. Schreiber S et al. "An open trial of plant-source derivedphosphatidylserine for treatment of age-related cognitive decline." IsrJ Psychiatry Relat Sci. 37, 4:302-7, 2000.

70. Jorissen BL et al. "The influence of soy-derived phosphatidylserineon cognition in age-associated memory impairment." Nutr Neurosci. 4,2:121-34, 2001. www.tandf.co.uk/journals/titles/1028415x.html

71. Fiorvanti M, Yanagi M. "Cytidinediphosphocholine (CDP choline) forcognitive and behavioral disturbances associated with chronic cerebral disordersin the elderly." Cochrane Database Syst Rev. 2:CD000269, 2004. www.medlib.com/spi/cdsr.htm

72. Conant R, Schauss AG. "Therapeutic applications of citicoline forstroke and cognitive dysfunction in the elderly: a review of theliterature." Altern Med Rev. 9, 1:17-31, 2004. www.thorne.com/altmedrev

73. Teather LA, Wurtman RJ. "Dietary cytidine (5')-diphosphocholinesupplementation protects against development of memory deficits in agingrats." Prog Neuropsychopharmacol Biol Psychiatry. 27, 4:711-7, 2003.

74. Plataras C, Angelogianni P, Tsakiris S. "Effect of CDP-choline onhippocampal acetylcholinesterase and NA+,K(+)-ATPase in adult and agedrats." Z Naturforsch [C]. 58, 3-4:277-81, 2003.

75. Crespo D et al. "Chronic treatment with a precursor of cellularphosphatidylcholine ameliorates morphological and behavioral effects of aging inthe mouse hippocampus." Ann NY Acad Sci. 1019:41-3, 2004. www.nyas.org/publications/annals/

76. Cohen RA et al. "Long-term citicoline (cytidine diphosphate choline)use in patients with vascular dementia: neuroimaging and neuropsychologicaloutcomes." Cerebrovasc Dis. 16, 3:199-204, 2003.

77. Abad-Santos F et al. "[Treatment of mild cognitive impairment: valueof citicoline.]" Rev Neurol. 35, 7:675-82, 2002.

78. Virmani A, Binienda Z. "Role of carnitine esters in brainneuropathology." Mol Aspects Med. 25, 5-6: 533-49, 2004. www.sciencedirect.com/science/journal/00982997

79. Pettegrew JW, Levine J, McClure RJ. "Acetyl-L-carnitinephysical-chemical, metabolic and therapeutic properties: relevance for its modeof action in Alzheimer's disease and geriatric depression." MolPsychiatry. 5, 6:616-32, 2000.

80. Liu J et al. "Memory loss in old rats is associated with brainmitochondrial decay and RNA/DNA oxidation: partial reversal by feedingacetyl-L-carnitine and/or R-alpha-lipoic acid." PNAS. 99, 4:2356-61,2002. www.pnas.org

81. Dhitavat S et al. "Acetyl-L-carnitine protects against amyloid-betaneurotoxicity: roles of oxidative buffering and ATP levels." NeurochemRes. 27, 6:501-5, 2002.

82. Ando S et al. "Enhancement of learning capacity and cholinergicsynaptic function by carnitine in aging rats." J Neurosci Res. 66,2:266-71, 2001.

83. Hudson S, Tabet N. "Acetyl-L-carnitine for dementia." CochraneDatabase Syst Rev. 2:CD003158, 2003. www.medlib.com/spi/cdsr.htm

84. Montgomery SA, Thal LJ, Amrein R. "Meta-analysis of double blind,randomized, controlled clinical trials of acetyl-L-carnitine versus placebo inthe treatment of mild cognitive impairment and mild Alzheimer's disease." IntClin Psychopharmacol. 18, 2:61-71, 2003.

85. Bianchetti A, Rozzini R, Trabucchi M. "Effects of acetyl-L-carnitinein Alzheimer's disease patients unresponsive to acetylcholinesteraseinhibitors." Curr Med Res Opin. 19, 4:350-3, 2003.

86. Beal MF. "Mitochondrial dysfunction and oxidative damage inAlzheimer's and Parkinson's diseases and coenzyme Q10 as a potentialtreatment." J Bioenerg Biomembr. 36, 4:381-6, 2004.

87. Ebadi M et al. "Ubiquinone (coenzyme q10) and mitochondria inoxidative stress of Parkinson's disease." Biol Signals Recept. 10,3-4:224-53, 2001. www.karger.com/journals/bsi/bsi_jh.htm

88. Andrich J et al. "Coenzyme Q10 serum levels in Huntington'sdisease." J Neural Transm Suppl. 68:111-6, 2004.

89. McCarthy S et al. "Paraquat induces oxidative stress and neuronalcell death; neuroprotection by water-soluble Coenzyme Q10." Toxicol ApplPharmacol. 201, 1:21-31, 2004.

90. McDaniel MA, Maier SF, Einstein GO. ""Brain-specific"nutrients: a memory cure?" Nutrition. 19, 11-12:957-75, 2003. www.elsevier.com/locate/nut

91. Szatmari SZ, Whitehouse PJ. "Vinpocetine for cognitive impairmentand dementia." Cochrane Database Syst Rev. 1:CD003119, 2003. www.medlib.com/spi/cdsr.htm

92. Pereira C, Agostinho P, Oliveira CR. "Vinpocetine attenuates themetabolic dysfunction induced by amyloid beta-peptides in PC12 cells." FreeRad Res. 33, 5:497-506, 2000. www.tandf.co.uk/journals

93. Birks J, Grimley EV, Van Dongen M. "Ginkgo biloba for cognitiveimpairment and dementia." Cochrane Database Syst Rev. 4:CD003120,2002. www.medlib.com/spi/cdsr.htm

94. Kurz A, Van Baelen B. "Ginkgo biloba compared with cholinesteraseinhibitors in the treatment of dementia: a review based on meta-analyses by theCochrane collaboration." Dement Geriatr Cogn Disord. 18, 2:217-26,2004.

95. Andrieu S et al. "Association of Alzheimer's disease onset withginkgo biloba and other symptomatic cognitive treatments in a population ofwomen aged 75 years and older from the EPIDOS study." J Gerontol A BiolSci Med Sci. 58, 4:372-7, 2003.

96. van Dongen M et al. "Ginkgo for elderly people with dementia andage-associated memory impairment: a randomized clinical trial." J ClinEpidemiol. 56, 4:367-76, 2003.

97. Le Bars PL et al. "Influence of the severity of cognitive impairmenton the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease."Neuropsychobiology. 45, 1:19-26, 2002.

98. Mix JA, Crews WD Jr. "A double blind, placebo-controlled, randomizedtrial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact olderadults: neuropsychological findings." Hum Psychopharmacol. 17,6:267-77, 2002. www.interscience.wiley.com/jpages/0885-6222

99. Cieza A, Maier P, Poppel E. "[The effect of ginkgo biloba on healthyelderly subjects."] Fortschr Med Orig. 121, 1:5-10, 2003.

100. Das A et al. "A comparative study in rodents of standardizedextracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitiveenhancing activities." Pharmacol Biochem Behav. 73, 4:893-900, 2002.www.elsevier.com/locate/pharmbiochembeh

101. Nathan PJ et al. "Effects of a combined extract of Ginkgo bilobaand Bacopa monniera on cognitive function in healthy humans." HumPsychopharmacol. 19, 2:91-6, 2004. www.interscience.wiley.com/jpages/0885-6222

102. Roodenrys S et al. "Chronic effects of Brahmi (Bacopa monnieri) onhuman memory." Neuropsychopharmacology. 27, 2:279-81, 2002.

103. Stough C et al. "The chronic effects of an extract of Bacopamonniera (Brahmi) on cognitive function in healthy human subjects." Psychopharmacology(Berl). 156, 4:481-4, 2001.

104. Rai D et al. "Adaptogenic effect of Bacopa monniera (Brahmi)."Pharmacol Biochem Behav. 75, 4:823-30, 2003. www.elsevier.com/locate/pharmbiochembeh

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like